Type 2 diabetes mellitus
Conditions
Interventions
Subjects take Canagliflozin 100mg once a day 1 for 12 weeks.
Sponsors
Nakakinen clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) HbA1c levels of >=6.5% to <8.5% (NGSP) 2) Age >=20 to <75 years on the date of submission of informed consent 3) Under treatment with fixed diet and exercise therapy >=8weeks 4) When treated with oral antidiabetic drugs; under treatment with a fixed dose and regimen >=8 weeks 5) Submission of written informed consent for participation in this study
Exclusion criteria
Exclusion criteria: 1) Type 1 diabetes, diabetes due to a pancreatic disorder, or secondary diabetes due to conditions 2) Application of contraindications contained in the package insert 3) Severe renal function disorder 4)BMI is < 22kg/m2 5) Under treatment with insulin,GLP-1 analog, or SGLT2 inhibitor 6) Pregnant women, women suspected of being pregnant, or lactating women 7) Participation in the study is judged by the investigator or sub-investigator as inappropriate for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postprandial changes in glucose and GLP-1 levels after 12 weeks of treatment with canagliflozin | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Change in glycemic parameters, body weight, waist circumference, and glucagon after 12 weeks of treatment with canagliflozin. 2) Continuous glucose monitoring | — |
Countries
Japan
Contacts
Public ContactKensuke Ofuchi
Nakakinen clinic Clinical Laboratory
Outcome results
None listed